CalciMedica (NASDAQ:CALC) Announces Earnings Results, Beats Estimates By $1.03 EPS

CalciMedica (NASDAQ:CALC) issued its quarterly earnings data on Tuesday. The company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($1.27) by $1.03, FiscalAI reports.

CalciMedica Stock Down 3.2%

Shares of NASDAQ CALC traded down $0.05 during trading on Tuesday, reaching $1.47. The company had a trading volume of 1,436 shares, compared to its average volume of 175,516. CalciMedica has a 12-month low of $1.00 and a 12-month high of $36.00. The company has a quick ratio of 5.58, a current ratio of 5.58 and a debt-to-equity ratio of 1.67. The business’s 50-day moving average is $1.60 and its 200 day moving average is $3.50. The stock has a market cap of $10.01 million, a PE ratio of -0.22 and a beta of 0.84.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on CALC shares. UBS Group reissued a “neutral” rating on shares of CalciMedica in a research report on Thursday, August 13th. HC Wainwright reaffirmed a “neutral” rating on shares of CalciMedica in a research note on Wednesday, July 29th. Weiss Ratings raised CalciMedica from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 27th. Guggenheim initiated coverage on shares of CalciMedica in a report on Thursday, August 20th. They set a “buy” rating on the stock. Finally, Wall Street Zen lowered shares of CalciMedica from a “sell” rating to a “strong sell” rating in a research note on Saturday, September 12th. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, CalciMedica has an average rating of “Hold” and a consensus target price of $50.00.

About CalciMedica

CalciMedica, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for serious inflammatory and immune-mediated diseases. The company’s research centers on calcium release-activated calcium (CRAC) channels, which help regulate immune-cell activation and inflammatory responses.

CalciMedica’s lead product candidate is zelnecirnon, formerly known as Auxora or CM4620. It is an investigational, selective CRAC channel inhibitor being evaluated as a potential treatment for acute inflammatory conditions, including severe acute pancreatitis and associated organ injury.